Stockscreener 앱 받기
6.61
5.57%
-0.39
시간 외 거래:
6.70
0.09
+1.36%
전일 마감가:
$7.00
열려 있는:
$5.86
하루 거래량:
134.37K
Relative Volume:
3.08
시가총액:
$611.37M
수익:
$5.12M
순이익/손실:
$-67.00M
주가수익비율:
-4.4966
EPS:
-1.47
순현금흐름:
$-38.94M
1주 성능:
-19.02%
1개월 성능:
+10.17%
6개월 성능:
-8.55%
1년 성능:
-90.88%
1일 변동 폭
$5.86
$6.78
1주일 범위
$5.86
$8.16
52주 변동 폭
$3.816
$73.40
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.61 | 64.74M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
What analysts say about Verrica Pharmaceuticals Inc. stockExceptional return forecasts - PrintWeekIndia
What drives Verrica Pharmaceuticals Inc. stock priceFree Stock Selection - PrintWeekIndia
Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialFree Consultation - Newser
VRCA Trading Halted: Anticipation Builds for Pending Announcemen - GuruFocus
Is Verrica Pharmaceuticals Inc. stock a good hedge against inflationRemarkably fast returns - jammulinksnews.com
Verrica Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - Autocar Professional
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Reverse Stock Split - TipRanks
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split - Investing.com
Is Verrica Pharmaceuticals Inc. a good long term investmentAccelerated earnings growth - jammulinksnews.com
Published on: 2025-07-19 07:38:47 - jammulinksnews.com
What institutions are buying Verrica Pharmaceuticals Inc. stock nowDaily Trade Opportunity - Newser
What makes Verrica Pharmaceuticals Inc. stock price move sharplyInsider Strategy Insight - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - newser.com
How Verrica Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Community - Newser
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Average Target Price from Brokerages - Defense World
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates - MyChesCo
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% – Should You Sell? - Defense World
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 | VRCA Stock News - GuruFocus
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales - Investing.com
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Commo - GuruFocus
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):